TFF Pharmaceuticals Shares Slump After Board Approves Dissolution

MT Newswires Live2024-11-15

TFF Pharmaceuticals (TFFP) shares tumbled 72% in premarket activity Friday a day after the board approved the company's dissolution and liquidation.

The company plans to call a special stockholders' meeting to seek approval of the dissolution plan, according to a filing with the US Securities and Exchange Commission.

TFF said it has terminated its employees in connection with the planned wind down of its operations.

The company also said Chief Executive Harlan Weisman, Chief Financial Officer Kirk Coleman and Chief Medical Officer Zamaneh Mikhak have stepped down from their respective positions as of Nov. 14. TFF Pharmaceuticals said its board named Craig Jalbert as chief executive, president and chief financial officer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment